Overview

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
0
Participant gender:
All
Summary
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Aging (NIA)
Treatments:
Guanfacine
Criteria
Inclusion Criteria:

Subjects enrolled will be nondemented, male and female individuals who meet the following
inclusion criteria:

- 75 years of age or older

- Fluent in English

- Stable medical condition for at least 4 weeks prior to Screening visit

- Stable dose of non-excluded medications for at least 4 weeks prior to Screening visit

Exclusion Criteria:

- Dementia

- Mild Cognitive Impairment (Amnestic MCI)

- Clinically significant neurologic disease

- Clinically significant or unstable medical conditions that would interfere with
participation in the trial

- Known hypersensitivity to guanfacine

- History of alcohol or substance abuse or dependence within the past 5 years

- Active major psychiatric disorders, including major depression

- History of mental retardation

- Significant abnormalities on clinical laboratories, ECG, or physical examination

- Impairment of visual or auditory acuity sufficient to interfere with completion of
study procedures

- Education level < 6 years